Meeting
2018 ASCO Annual Meeting
Doxorubicin (D), gemcitabine (G), ifosfamide (I) and the EZH2 inhibitor EPZ-011989 in epithelioid sarcoma (ES): A comparison of different regimens in a patient-derived xenograft (PDX) model.
Authors
Nadia Zaffaroni
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Nadia Zaffaroni , Anna Maria Frezza , Valentina Zuco , Alessandro Gronchi , Chiara Colombo , Sandro Pasquali , Paolo Giovanni Casali , Angelo Paolo Dei Tos , Paola Collini , Maria A. Pantaleo , Annalisa Astolfi , Valentina Indio , Monica Tortoreto , Silvia Stacchiotti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 36, 2018 (suppl; abstr 11578)
DOI
10.1200/JCO.2018.36.15_suppl.11578
Abstract #
11578
Poster Bd #
323
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2020 ASCO Virtual Scientific Program
A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma.
First Author: Shiraj Sen
Poster
2019 ASCO Annual Meeting
Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS).
First Author: Nam Bui
Poster
2019 Genitourinary Cancers Symposium
Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies.
First Author: Pavlos Msaouel